Delivery Order SPE2DP20D0002-SPE2DP26F0981
Award Date 12/1/25
Potential Completion Date 12/9/25
Potential Value $165K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of Defense's Medical Supply Chain awarded Teva Pharmaceuticals USA, Inc. a $165,156.93 firm fixed-price delivery order for Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. This delivery order, issued December 1, 2025, represents a continuation of Teva's critical role as a primary supplier under an existing indefinite delivery contract vehicle with the Defense Logistics Agency Troop Support Medical. The award carries no set-aside designation and...
- The U.S. Department of Defense's Medical Supply Chain awarded a $1.32 million firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with performance scheduled for completion by December 9, 2025. This delivery order, issued without set-aside designation, represents one of over 150 awards Teva has received since 2023 under indefinite delivery contract vehicles, primarily through the Defense Logistics Agency Troop Support Medical. The vaccine will be...
- The Department of Defense's Medical Supply Chain awarded a $165,156.93 delivery order to Teva Pharmaceuticals USA, Inc. on December 1, 2025, for the supply of Adenovirus Type 4 vaccine. This firm-fixed-price delivery order, with an ultimate completion date of December 9, 2025, represents part of Teva's extensive portfolio supporting critical military immunization programs. The contract contains no set-aside designation and will be performed at Teva's manufacturing facility in Parsippany, New...
- The Department of Defense's Medical Supply Chain issued a delivery order valued at $1.98M to Teva Pharmaceuticals USA, Inc. for the supply of Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. This firm-fixed-price delivery order, issued without set-aside designation, represents one of over 150 similar awards to Teva since 2023 under indefinite delivery contract vehicles managed by the Defense Logistics Agency Troop Support Medical. The Adenovirus Type 4 vaccine...
- The U.S. Department of Defense's Medical Supply Chain, through the Defense Logistics Agency Troop Support Medical, awarded a $330,313.86 firm-fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine. The contract, issued on June 16, 2025, with an ultimate completion date of June 24, 2025, carries no set-aside designation and will be performed at Teva's facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as...
- The U.S. Department of Defense, through its Medical Supply Chain division, awarded a firm-fixed-price delivery order valued at $825,784.65 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine. The contract was issued on July 14, 2025, with an ultimate completion date of July 29, 2025, and will be performed at Teva's facility in Parsippany, New Jersey. This delivery order was not subject to any small business set-aside designation, reflecting Teva's status as a large business competing...
- The U.S. Department of Defense's Medical Supply Chain division awarded a $1.16M firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with an ultimate completion date of August 26, 2025. The contract, which carries no set-aside designation, will be performed at Teva's manufacturing facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as a critical supplier of vaccines and pharmaceutical products to...
- The U.S. Department of Defense, through the Defense Logistics Agency Troop Support Medical, awarded a delivery order valued at $330,313.86 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine. The contract, awarded on July 14, 2025, with a completion date of July 29, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. Performance will be conducted at Teva's facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's...
- The Department of Defense's Medical Supply Chain, functioning under defense operations, awarded a delivery order valued at approximately $826K to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine. This contract, issued on August 12, 2025, with an ultimate completion date of August 26, 2025, carries a firm fixed price structure and was awarded without a set-aside designation. The work will be performed in Parsippany, New Jersey, where Teva maintains its headquarters as a subsidiary...
- Teva Pharmaceuticals USA, Inc. was awarded a $660,627.72 firm fixed-price delivery order for Adenovirus Type 4 vaccine, with an ultimate completion date of July 29, 2025. This contract, issued by the Medical Supply Chain division within the Department of Defense, represents a non-set-aside award structured as a delivery order under what appears to be a larger indefinite delivery contract vehicle. The work will be performed in Parsippany, New Jersey, where Teva maintains its primary manufacturing...